<DOC>
	<DOCNO>NCT01396733</DOCNO>
	<brief_summary>Radioiodine ( I-131 ) therapy proven efficacy treatment differentiate thyroid carcinoma ( DTC ) . However , loss differentiation recurrent metastatic DTC decrease I-131 uptake may decrease efficacy I-131 therapy . Therefore , strategy improve I-131 uptake mandatory . This study open label clinical study evaluate effectiveness alpha-lipoic acid ( ALA ) improve I-131 uptake recurrent metastatic DTC defective I-131 uptake .</brief_summary>
	<brief_title>Redifferentiation Therapy Using Alpha Lipoic Acid Thyroid Cancer</brief_title>
	<detailed_description />
	<mesh_term>Thyroid Diseases</mesh_term>
	<mesh_term>Thyroid Neoplasms</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>1. age 20 75 year 2. birth control , fertile woman 3 . Groups receive radioactive iodine treatment recurrent metastatic thyroid cancer , show uptake posttherapeutic whole body scan plan receive empirical radioactive treatment due high expect recurrence allergic alphalipoic acid severe heart failure , lung disease , endstage renal disease liver function abnormality ( x2.5 normal limit ) neuropsychologically unstable patient previous history drug medication oral steroid , digoxin , theophylline , carbamazepine , valproic acid , phenobarbital , methotrexate , cyclosporin , tacrolimus within 3 month recruitment . already take alphalipoic acid purpose .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>thyroid</keyword>
	<keyword>cancer</keyword>
	<keyword>redifferentiation</keyword>
	<keyword>lipoic acid</keyword>
</DOC>